Meanwhile, the S&P BSE Sensex was down 121.25 points or 0.37% at 33,054.75. The S&P BSE Mid-Cap index fell 1.35%, underperforming the Sensex.

On the BSE, 61,000 shares were traded on the counter so far as against the average daily volumes of 4,313 shares in the past one quarter. The stock had hit a high of Rs 514.90 and a low of Rs 467.20 so far during the day. The stock had hit a 52-week high of Rs 748.95 on 12 April 2017 and a 52-week low of Rs 401 on 8 March 2018.

The mid-cap company has equity capital of Rs 8.15 crore. Face value per share is Rs 1.

The United States Food and Drug Administration (USFDA) issued an Establishment Inspection Report (EIR) for Shilpa Medicare's formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, which was inspected between 11 November and 30 November 2017. USFDA has determined that the inspection classification of this facility is VAI and accordingly EIR issued. The company added that earlier status of its formulation unit is maintained.

On a consolidated basis, Shilpa Medicare's net profit fell 0.9% to Rs 17.30 crore on 2% growth in net sales to Rs 185.53 crore in Q3 December 2017 over Q3 December 2016.

Shilpa Medicare is engaged in the business of bulk drugs manufacturing.